An Investigation of the Effect of Cagrilintide and Semaglutide Combination Treatment(CagriSema) on Energy Intake, Appetite and Gastric Emptying in People With Overweight or Obesity
Latest Information Update: 13 Jan 2025
At a glance
- Drugs Cagrilintide/semaglutide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Novo Nordisk
Most Recent Events
- 07 Jan 2025 Status changed from recruiting to completed.
- 13 Mar 2024 Planned End Date changed from 1 Jan 2025 to 8 Dec 2024.
- 13 Mar 2024 Status changed from not yet recruiting to recruiting.